Incidence of Neutralizing Antibodies in Cynomolgus Monkeys

This case study examines the incidence of neutralizing adeno-associated viral (AAV) antibody subtypes in cynomolgus monkeys from Cambodian, Mauritian, and Philippine origins. It details the significance of seroconversion, which is the development of detectable antibodies in response to an infection or vaccination. The study highlights the challenges of using cynomolgus macaques in AAV vector-based gene therapy due to the presence of naturally occurring neutralizing antibodies. A review of prescreening data indicates no substantial differences in seronegativity rates between the tested origins, except for AAV9, where variability was observed. The findings suggest that understanding pre-existing antibodies is crucial for optimizing the safety and efficacy of AAV-based therapies. The document also outlines the methodology for screening nonhuman primates for pre-existing antibodies and discusses the implications for study design in gene therapy research. Variations in seronegativity rates across different AAV serotypes were noted, emphasizing the need for careful selection of animal models in therapeutic studies.